AKL RESEARCH & DEVELOPMENT
A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.
AKL RESEARCH & DEVELOPMENT
Industry:
Pharmaceutical
Founded:
2013-09-20
Address:
Stevenage, Herefordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.aklrd.com
Total Employee:
11+
Status:
Active
Total Funding:
675 K GBP
Technology used in webpage:
SPF DoubleClick.Net DMARC Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Network Solutions DNS Network Solutions Google Analytics Enhanced Link Attribution
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aristea Therapeutics
Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.
Clario
Clario delivers the endpoint technology solutions for clinical trials.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Investors List
Innovate UK
Innovate UK investment in Grant - AKL Research & Development
Official Site Inspections
http://www.aklrd.com
- Host name: 209.17.116.163
- IP address: 209.17.116.163
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
More informations about "AKL Research & Development"
AKL Research & Development - Crunchbase Company …
A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative …See details»
AKL Research and Development Ltd - VentureRadar
AKL Research & Development is a privately held, pharmaceutical company, with an innovative approach to drug development. AKLRD identifies and synthesizes secondary metabolites of …See details»
AKL Research & Development - Datanyze
AKL Research & Development (AKLRD) Ltd's primary focus is inflammatory diseases, particularly those related to the disruption of the immune system, such as OA. It identifies secondary …See details»
AKLRD - PharmiWeb.com
AKLRD Research & Development. AKL Research & Development Limited is a privately held, pharmaceutical company, with an innovative approach to drug development. AKLRD is …See details»
AKL Research & Development - Overview, News & Similar
Apr 29, 2021 Who is AKL Research & Development. AKL Research & Development (AKLRD) Ltd's primary focus is inflammatory diseases, particularly those related to the disruption of the …See details»
AKL Research & Development Ltd. - Drug pipelines, Patents
Www.aklrd.com. Private Company | 2013 | United Kingdom | 10-50 | www.aklrd.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. ... The statistics for …See details»
AKL Research & Development Ltd - ContactOut
Discover AKL Research & Development Ltd company details, including staff directory, contact information, and industry insights. Explore alternatives, competitors, and frequently asked …See details»
AKL Research and Development (AKLRD) - News, Articles etc.
Feb 18, 2019 AKL Research and Development (AKLRD) Show advanced filters. Reset all . news Biotech firm awarded for approach to drug development. 18 February 2019 | By European …See details»
Former Investment Banker Appointed CFO of AKL Research
STEVENAGE, England, Aug. 20, 2019 /PRNewswire/ -- AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, today …See details»
AKLRD - Pharma Journal
A privately held pharmaceutical company with a cutting-edge approach to medication research is AKL Research & Development Limited. For inflammatory disorders with a high unmet demand, …See details»
UK-based Biotech Company, AKLRD, Rewarded for Unique …
Feb 18, 2019 Additional information on APPA, including a Mode of Action graphic, Osteoarthritis and AKLRD is available on request. [1] Cross A, et al. Effects of APPA on human neutrophil …See details»
UK-based Biotech Company, AKLRD, Rewarded for Unique
AKL Research and Development announces its investigational medicine for osteoarthritis (OA) has been awarded a prestigious grant from Innovate UK, the leading government innovation …See details»
Dr Annalisa Jenkins and Lord Michael Grade Appointed as …
Dec 11, 2018 AKLRD is dedicated to novel approaches to drug development through collaborations with companies which are embracing innovation with the shared common …See details»
AKL Research & Development’s Novel Osteoarthritis Medicine …
David Miles, CEO of UK-based AKLRD, says: “Osteoarthritis is a debilitating condition which has a devastating impact on the daily lives of millions of people. Moving to a Phase II trial is a …See details»
AKL Research and Development partner with world-leading animal …
Stevenage, UK, 28 July 2020 – AKL Research and Development (AKLRD), a pharmaceutical company developing an investigational osteoarthritis (OA) medicine, has signed an agreement …See details»
210429 AKLRD OARSI Press Release WEBSITE VERSION (002)
[email protected] Alexandra Harrison The Difference Collective T: 07525 144230 [email protected] NOTES TO EDITORS: About APPA APPA is …See details»
AKL Research & Development's novel osteoarthritis medicine …
Sep 18, 2020 David Miles, CEO of UK-based AKLRD, says: "Osteoarthritis is a debilitating condition which has a devastating impact on the daily lives of millions of people. Moving to a …See details»
AKL Research & Development's novel osteoarthritis ... - Markets …
Sep 18, 2020 STEVENAGE, England and COPENHAGEN, Denmark, Sept. 18, 2020 /PRNewswire/ -- A novel, oral osteoarthritis (OA) medicine being developed by AKL Resea...See details»
New data presented at OARSI 2021 Virtual World Congress by AKL …
Apr 29, 2021 Findings suggest APPA's mode of action targets multiple pathways involved in osteoarthritis. STEVENAGE, England, April 29, 2021 /PRNewswire/ -- AKL Research and …See details»
AKL Research & Development and Nordic Bioscience Collaborate …
TORONTO, May 2, 2019 /PRNewswire/ -- AKL Research & Development (AKLRD) and Nordic Bioscience Clinical Development, today announce a risk-share agreement to assess the …See details»